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Summary 
T cell activation through the TCR can result in either 
cell proliferation or cell death. The role of costlmula- 
tory receptors in regulating T cell survival has not been 
defined. Here, we present data demonstrating that 
CD28 costimulation enhances the in vitro survival of 
activated T cells. One mechanism for this enhance- 
ment is the ability of CD28 costimulation to augment 
the,production of IL-2, which acts as an extrinsic sur- 
vival factor for T cells. In addition, CD28 costimulation 
augments the intrinsic ability of T cells to reslst apop 
tosis. Although CD28 signal transduction had no effect 
on Bcl-2 expression, CD28 costimulatlon was found 
to augment the expression of Bcl-xL substantially. 
Transfection experiments demonstrated that this level 
of Bcl-XL could prevent T cell death in response to TCR 
cross-linking, Fas cross-linking, or IL-2 withdrawal. 
These data suggest that an Important role of CD28 co- 
stimulation is to augment T cell survival during antigen 
activation. 
Introduction 
Tcell activation is initiated by the engagement of the Tcell 
receptor (TCR)-CD3 complex (TCR-CD3) by a peptide- 
antigen bound to a major histocompatibility complex 
(MHC) molecule on the surface of an antigen-presenting 
cell (APC) (Schwartz, 1990). While this is the primary sig- 
nal in T cell activation, other receptor-ligand interactions 
between APCs and T cells are required for complete acti- 
vation. For example, TCR stimulation in the absence of 
other molecular interactions can induce a state of anergy, 
such that these cells can not respond to full activation 
signals upon restimulation (Schwartz, 1990; Harding et 
al., 1992). Alternatively, T cells have been shown to die 
by programmed cell death (PCD) when activated by TCR 
engagement alone (Webb et al., 1990; Kawabe and Ochi, 
1991; Kabelitz and Wesselborg, 1992; Groux et al., 1993). 
There are multiple receptor-ligand interactions, which 
take place between the T cell and the APC. Many interac- 
tions are adhesive in nature and reinforce the contact be- 
tween the two cells (Springer et al., 1987), while other 
interactions transduce additional activation signals to the 
T cell (Bierer and Burakoff, 1991). CD28, a surface glyco- 
protein present on 80% of peripheral T cells in humans, 
has been shown to be an important costimulatory receptor 
(Juneet al., 1994; Linsleyand Ledbetter, 1993). Acostimu- 
latory signal is transduced through CD28 when T cells 
encounter an APC expressing either of the CD28 ligands 
87-l or 87-2. 
Costimulation of T cells has been shown to affect multi- 
ple aspects of T cell activation (June et al., 1994). Costimu- 
lation will lower the concentration of anti-CD3 required to 
induce a proliferative response in culture (Gimmi et al., 
1991). CD28 costimulation also markedly enhances the 
production of lymphokines by helper T cells through tran- 
scriptional and posttranscriptional regulation of gene ex- 
pression (Lindsten et al., 1989; Fraser et al., 1991), and 
can activate the cytolytic potential of cytotoxic Tcells. Inhi- 
bition of CD28 costimulation in vivo can block xenograft 
rejection and allograft rejection is significantly delayed 
(Lenschow et al., 1992; Turka et al., 1992). In addition, 
transfection of 87 into a tumor cell line facilitates recogni- 
tion and prevention of tumor growth (Chen et al., 1992; 
Townsend and Allison, 1993). 
While much is known about how costimulation affects 
the proliferative aspects of T cell activation, little is known 
about the role of CD28 in providing signals that affect T 
cell survival. The control of peripheral T cell survival is 
critical to the maintenance of an effective peripheral im- 
mune repertoire. Until recently, relatively little has been 
known about how peripheral T cell survival is controlled. 
Recently, several genes have been identified that appear 
to play critical roles in regulating T cell survival. The sur- 
vival of quiescent lymphocytes in the mouse is dependent 
on the expression of the 6~1-2 gene (Nakayama et al., 
1993). Animals deficient in the bcl-2 gene have T cells 
with an increased susceptibility to undergo PCD when 
placed in culture. Bcl-a-deficient animals become pro- 
foundly lymphopenic within the first few weeks of life (Veis 
et al., 1993a). In contrast, animals with mutations in the 
Fas cell surface receptor fail to clear the excess immune 
cells generated in the course of an immune response (Wa- 
tanabe-Fukunaga et al., 1992). Fas-deficient animals ulti- 
mately develop profound autoimmune disease. These 
data suggest that T cell survival is just as tightly regulated 
as T cell proliferation. 
Some aspects of T cell survival appear to be linked to 
the state of T cell activation. Previously published data 
suggest that mitogen activation of T cells enhances their 
resistance to PCD initiated by treatment with such agents 
as radiation (Schrek and Stefani, 1964; Lowenthal and 
Harris, 1985; Stewartet al., 1988). Incontrast,Tcell activa- 
tion through the TCR alone has been reported to increase 
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Figure 1, The State of T Cell Activation Affects the Survival of T Cells 
Following y Irradiation 
Purified T cells were cultured in medium (open squares), stimulated 
with anti-CD3 (open diamonds), or with anti-CD3 plus anti-CD23 
(closed squares) for 12 hr. Cells from each of these three groups were 
then split into two groups. One group was cultured without further 
manipulation ([A], 0 Gy), while the other group was subjected to 15 
Gy of y irradiation ([B], 15 Gy). The graphs show the percent viability 
of each group as assessed by propidium iodide exclusion and total 
cell accumulation as assessed by trypan blue exclusion (data not 
shown) daily over 4 days. The data presented represent the mean and 
standard deviation of three consecutive experiments. 
the susceptibility of T cells to undergo PCD (Kabelitz and 
Wesselborg 1992; Grouxet al., 1993). One potential mech- 
anism by which mitogen-activated and antigen-activated 
T cells may differ is through the activation of costimulatory 
receptors such as CD28. 
In this report, we have examined the role of T cell costi- 
mulation through the CD28 receptor on the survival of acti- 
vated T cells. We show that costimulation through CD28 
enhances the survival of Tcells activated through the anti- 
gen receptor, not only by enhancing the production of 
growth factors such as interleukin-2 (IL-2) but also by up- 
regulating the expression of the cell survival factor Bcl-XL. 
Both the expression of extrinsic growth factors such as 
IL-2 and intrinsic cell survival factors such as Bcl-XL play 
a role in the initial survival of T cells activated through 
their antigen receptor. 
Results 
Activation Enhances T Cell Survival 
Following 7 Irradiation 
To study the effects of T cell activation pathways on T cell 
survival, resting T cells were isolated from human periph- 
eral blood by negative selection as previously described 
(June et al., 1987). The resulting cells were then cultured 
in medium alone or stimulated by cross-linking the TCR- 
CD3 complex in the presence or absence of costimulation 
provided by a CD28specific monoclonal antibody (MAb). 
All three populations of cells maintained high viability over 
the 4 day culture period (Figure 1A). The survival of resting 
and activated T cells was also examined following expo- 
sure to 7 irradiation (Figure 1B). 7 irradiation-induced 
apoptosis does not require a specific receptor-ligand in- 
teraction and thus can be considered as a tool to study 
how cell activation influences ceil survival without the need 
to control for specific receptor levels. The dose used in 
these assays (15 Gy) is sufficient to induce lethal DNA 
damage in virtually all cells in the population. Thus, the 
rate at which the cells die over the ensuing days can be 
used as a measure of their ability to resist undergoing 
PCD in response to DNA damage. Following irradiation, 
the viability of resting T cells declined much more rapidly 
than it did in either population of stimulated lymphocytes. 
At 4 days postirradiation, T cells in either activated popula- 
tion were statistically more likely to be alive than cells 
in the resting population (p < 0.02). Cells costimulated 
through the CD28 receptor demonstrated a slight, but re- 
producible, enhancement in survival over cells stimulated 
with anti-CD3 alone. The maintenance of cell viability in 
anti-CD3-stimulated and anti-CD3 plus antiCD28stim 
ulated cells was not the result of subsequent T cell prolifera- 
tion, as cell counts done in parallel to the viability assays 
revealed that the absolute cell number did not change 
(data not shown). Furthermore, all the cells in the activated 
populations were arrested within the cell cycle at either 
late Gl or G2. Cell death in all three populations followed 
a classic apoptotic pattern with cells first becoming cre- 
nated, followed by nuclear condensation and DNA frag- 
mentation (data not shown). 
CD28 Costimulation Augments the Survival 
of Anti-CD&Activated T Cells 
Onedifference between cells stimulated in the presenceor 
absence of CD28 costimulation is the level of iymphokines 
produced by these cells (Lindsten et al., 1989). Previous 
evidence has suggested that growth factors play an im- 
portant role in the extrinsic regulation of cell survival in a 
varietyofcelltypes(Grouxet al., 1993; Nuifezet al., 1990). 
To determine whether the production of growth factors by 
T cells played a role in the autocrine regulation of their 
cell survival, T cells were activated by cross-linking of the 
TCR-CD3complex in the presence or absence of costimu- 
lation with an anti-CD28 MAb. As seen in Figure 2A, T cells 
activated through the TCR-CD3 complex alone maintain 
high viability in culture following activation. However, re- 
moval of conditioned medium by washing the stimulated 
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Figure 2. Survival of Activated T Cells Following y Irradiation in the Absence or Presence of Extrinsic Growth Factors 
Purified T cells were cultured for 12 hr with anti-CD3 alone (A and 8) or with anti-CD3 plus anti-CD28 (C and D) and then either left in their 
conditioned medium (open squares), washed and resuspended in fresh medium (open diamonds), or washed and resuspended in fresh medium 
supplemented with 200 U/ml of rlL-2 (closed squares). Aliquots from each group were then left unmanipulated (A and C) or subjected to 15 Gy 
of y irradiation (B and D). The graphs show viability of each cell group as assessed by propidium iodide exclusion daily for 4 days following 
manipulation. The graphs shown represent the mean and standard deviation of three independent experiments. 
cells led to a marked reduction in the ability of the cells 
to survive in culture. This reduced ability to survive in in 
vitro culture can be completely reversed by addition of 
IL-2. When anti-CD3-stimulated cells were subjected to 
15 Gy of y irradiation (Figure 28) removal of conditioned 
medium after overnight stimulation led to a sharp reduc- 
tion in cell viability, which was reversed by the addition 
of IL-2. This suggests that in antigen receptor-activated 
cells survival is primarily determined by the levels of extrin- 
sic growth factors. The ability of activated T cells to survive 
in culture is therefore based on their autocrine ability to 
produce growth factors such as IL-2. These data confirm 
that IL-2 is an extrinsic regulator of T cell survival. 
lncontrastwith theseresultsobserved withTcellsstimu- 
lated through the TCR-CD3 complex alone, T cells stimu- 
lated with a combination of anti-CD3 plus anti-CD28 do 
not differ in their survival, either when washed free of en- 
dogenously produced lymphokines or when further IL-2 
is added to the culture supernatants (Figures 2C, 2D). 
These results suggest that the costimulatory effects of 
anti-CD28 may lead to lymphokine levels so high that serial 
washing did not effectively deplete the cells of the growth 
factors needed to maintain cell viability. Alternatively, anti- 
CD28 costimulation may not only affect the production of 
extrinsic mediator8 of cell survival, but also may play a role 
in regulating the intrinsic susceptibility of cells to undergo 
PCD. 
bcl-2 and b&x mRNA Expreeeion During 
T Cell Activation 
To date, two genes, bcl-2 and bcl-xL, have been reported 
that can enhance the intrinsic ability of lymphocytes to 
survive (Nuftezet al., 1990; Boiseet al., 1993; Hockenbery 
et al., 1990). To investigate the role of CD28 in regulating 
the expression of genes involved in intrinsic resistance of 
T cells to undergo PCD, we have examined resting human 
T cells and T cells activated by cross-linking of the TCR 
antigen receptor complex in the presence or absence of 
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anti-CD28 for the expression of both bcl-x and 6~1-2. As 
seen in Figure 3A, neither b&x nor bcl-2 mRNA is ex- 
pressed at detectable levels in resting T cells. However, 
the expression of both bcl-2 and b&x mRNA is induced 
within 6 hr after T cell activation. CD26 costimulation had 
no significant effect on the expression of bcC2 mRNA. In 
contrast, CD26 costimulation enhanced the expression 
of bcl-x mRNA. We reproducibly observed a 3- to 5-fold 
increase in bcl-x mRNA beginning at the 6 hr timepoint 
following stimulation. Cells stimulated with anti-CD3 and 
anti-CD28 maintained high level expression of bcl-xfor 48 
hr, after which levels began to decline (data not shown). 
A third member of the bcl-2 family thought to have a nega- 
tive role in regulating the function of b&2 is the gene bax. 
Costimulation also had no affect on baxmRNA levels (data 
not shown). 
Alternative usage of the two 5’ splice donors in the first 
exon of bcl-x can yield two distinct mRNA species. bcl-xL 
retains the full coding region of exon 1 and functions to 
enhance cell survival. In contrast, use of an upstream 
splice donor site within exon 1 results in the bcl-xs mRNA, 
which contains a 169 bp deletion within the exon 1 coding 
region. The Bcl-xs protein appears to act as a dominant- 
negative regulator of both Bcl-2 and Bcl-xLfunctions (Boise 
et al., 1993; A. J. M., unpublished data). Since the bcl-xs 
and bcl-xL mRNAs differ by only 189 bp, RNase protection 
was performed to determine which bcl-x mRNA was in- 
duced upon T cell activation and costimulation (Figure 3B). 
Based on the RNase protection assay, the major b&x 
mRNA that is up-regulated by CD26 costimulation is bcl-x,. 
A small induction is also seen in levels of bcl-xs. 
T Cells Display Constitutive Expression 
of Bcl-2 Protein 
Since it has been previously reported that the levels of 
bcl-2 mRNA do not correlate well with the levels of Bcl-2 
protein (Chleq-Deschamps et al., 1993), we sought to con- 
firm our mRNA data by examining the expression of Bcl-2 
at the protein level during T cell activation. Immunoprecipi- 
tation and Western blot analyses were performed. As pre- 
Figure 3. mRNA Expression of bc-x and bcl-2 
(A) Northern blot analysis of bcl-x and k/-2 expression following T 
cell activation in the presence or absence of CD28 costimulation. RNA 
was isolated from cells cultured in medium alone (MED). or following 
stimulation with anti-CD3 (aCD3) or anti-CD3 plus anti-CD28 (c-CD3 
plus aCD28) for 1, 8, and 12 hr. The top shows ethidium bromide 
staining of an aliquot of each RNA sample following electrophoresis 
on a nondenaturing agarose gel. Northern blots were prepared as 
previously described (June et al., 1987) and probed sequentially with 
the human cc/-x, cDNA, mouse M-2 cDNA. and human HLA cDNA. 
(B) CD28 costimulation up-regulates bcl-x, mRNA expression. RNase 
protection assays were performed on RNA isolated from T cells that 
were either resting (0 hr) or stimulated for 8 or 12 hr with anti-CD3 
(aCD3) orantXD3 plus anti-CD28 (aCD3/aCD28). A radiolabeled ribo- 
probe was produced by in vitro transcription from the T3 promoter of 
Acci-digested ~/-XL plasmid, as described in Experimental Proce 
dures. The predicted sizes of protected fragments for bc/-xL and for 
bcl-xs are indicated. The data are representative of three independent 
experiments. 
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Figure 4. Expression of Bcl-2 and B&x Proteins Following T Cell Acti- 
vation 
Cytoplasmic extracts from resting purified T cells (0 hr) or T cells acti- 
vated with anti-CD3 (aCD3) or anti-CD3 plus anti-CD28 (aCD31aCD28) 
for 6, 12, and 24 hr were immunoprecipitated for either Bcl-x (top) or 
Bcl-2 (bottom) as described in Experimental Procedures. Immunopre- 
cipitates were resolved by SDS-PAGE and gels were transferred to 
nitrocellulose and immunoblotted for Bcl-x or Bcl-2 expression. The 
band at 28 kDa corresponds to Bcl-xL as determined by in vitro tran- 
scription/translation of the bcl-x,-containing plasmid as well as West- 
ern blot analysis of bcl-xL transfectants. Similar controls allowed us to 
establish that Bcl-xs is a 21 kDa protein when expressed, but no activity 
was detected in this size range (data not shown). The data are repre- 
sentative of three separate experiments 
viously shown, resting peripheral blood T cells expressed 
high levelsof Bcl-2 protein (Chleq-Deschamps et al., 1993; 
Reed et al., 1992). Furthermore, the levels of Bcl-2 protein 
do not vary significantly over the first 24 hr following TCR- 
CD3 receptor cross-linking with an anti-CD3 antibody (Fig- 
ure 4). Costimulation through the CD28 receptor also ap- 
peared to have no affect on Bcl-2 protein levels. 
CD28 Costimulatlon Enhances Bcl-xL 
Protein Expression 
Bcl-x protein levels varied significantly with the level of 
T cell activation (Figure 4). No detectable Bcl-x protein 
products were observed in resting peripheral blood Tcells. 
In vitro translated as well as transfected Bcl-XL protein is 
approximately 29 kDa in size, while Bcl-xS protein is ap- 
proximately 21 kDa(Figure 5; Boise et al., 1993). Anti-CD3 
stimulation of resting T cells induces the expression of 
detectable Bcl-xLprotein that was first observed 6 hr follow- 
ing stimulation and accumulated in the cell throughout the 
24 hr period of analysis. At no time was Bcl-xS protein 
observed. CD28 stimulation of resting T cells failed to in- 
43.6 kDa- 
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Figure 5. Bcl-x Expression Following T Cell Activation 
Resting T cells were activated for 24 hr with Medium alone, anti-CD28 
(aCD28), anti-CD3 (aCD3), anti-CD3 plus anti-CD28 (aCD3/aCD28), 
or anti-CD3 plus IL-2 (100 U/ml) (aCD3/lL-2). Cytoplasmic extracts 
were prepared as described in Experimental Procedures, and 100 pg 
of protein were subjected to SDS-PAGE and Western blot analysis 
with a polyclonal B&x sera. Bcl-xL mobility was determined from a 
positive control lane of lysate from FL5.12 cells transfected with 
pSFFVNeo-bcl-x, (B&x$ The data are representative of three sepa- 
rate experiments. 
duce Bcl-xL expression (Figure 5). However, CD28 co- 
stimulation of anti-CD3-stimulated cells significantly en- 
hanced the expression of Bcl-xL protein (see Figure 4; Fig- 
ure 5). The levels of expression of Bcl-xL in anti-CD3 plus 
anti-CD28-stimulated cells at 24 hr were similar to thO8e 
obtained in stable transfectants in which Bcl-xL is being 
expressed under control of the spleen focus-forming virus 
long terminal repeat (Figure 5). CD28 costimulation re- 
sulted in enhancement of Bcl-xL protein accumulation ob- 
servable as early as 6 hr following stimulation and continu- 
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Figure 6. Bcl-xL Expression Correlates with Resistance to Fas- 
Induced Cell Death 
T cells were activated with medium alone (Resting) or anti-CD3 plus 
antiCD28for a 120 hr time course. Cytoplasmic lysates were prepared 
and protein concentration quantitated by bicinchoninic acid assay. 
Protein (100 ug) was then subjected to SDS-PAGE and Western blot 
analysis as described in the Experimental Procedures. The polyclonal 
antisera was used for development of the Western blot. Simultaneous 
to Western blot analysis cells were treated with CH-11 (a-Fas) or an 
isotype-matched control (IgM) for 24 hr at each 24 hr interval of the 
120 hr timecourse as described in the Experimental Procedures. Via- 
bility was assessed by propidium iodide exclusion and cell death due 
to CH-11 treatment determined by normalizing to control antibody- 
treated cell viability. The percent viability at each timepoint is listed 
below the corresponding lane of the Western blot. These data are 
representative of three independent experiments. 
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ing throughout the 24 hr period of culture. In contrast, 
treatment of cells with anti-CD3 and IL-2 (100 U/ml) does 
not further enhance Bcl-xL expression above the levels 
seen in T cells treated with anti-CD3 alone (Figure 5). Fur- 
thermore, treatment of anti-CD3-activated T cells with 
MAbs to CD2, CD5, CD1 la, CD18, or to MHC class I does 
not enhance &I-xL levels above that of cells treated with 
anti-CD3 alone (data not shown). These data are consis- 
tent with the hypothesis that the specific induction of Bcl-xL 
as a result of CD28 costimulation plays a role in enhancing 
activated T cell survival. 
Bcl-xL Can Prevent Fas- and Anti-CDB-Induced PCD 
in Jurkat T Cells 
T cell activation has also been reported to induce the ex- 
pression of Fas. Cross-linking of Fas on T cell lines re- 
sults in the rapid induction of apoptosis. However, nor- 
mal T cells do not become susceptible to cell death in 
response to Fas cross-linking until they have been acti- 
vated for extended periods of time (Klas et al., 1993). Cells 
are rapidily induced to express high levels of Fas on the 
cell surface within 24 hr of activation with anti-CD3 plus 
antXD28. Fas levels then remain constant for the next 
several days in culture (data not shown). Despite this, the 
ability of Fas cross-linking to induce apoptosis does not 
become apparent until 72 hr after stimulation and then 
becomes increasingly more effective over the next several 
days in culture (Figure 6). This time course correlates 
closely with the down-regulation of Bcl-xL in these cells. 
As seen in Figure 6, following anti-CD3 plus anti-CD28 
costimulation, the peak of Bcl-xL expression is seen be- 
tween 24-48 hr and thereafter progressively declines. 
To test whether Bcl-xL expression could play a role in 
the regulation of Fas-mediated PCD, Jurkat T cells were 
transfected with pSFFVNeo-b&x‘ (Bcl-xL) or with the vec- 
tor alone (Neo) and several independent clones isolated 
(Figure 7A). Bcl-xL levels in the clones were verifed by 
Western blot. Bcl-xL levels in the bcl-xL transfectants were 
comparable to the levels expressed in T cells 24 hr after 
anti-CD3 plus anti-CD28 costimulation (for example, see 
Figure 5). Three Bcl-xL and three Neo clones, which ex- 
pressed comparable levels of Fas on their surface, were 
treated with a Fas antibody and viability assessed over 
time (Figure 7A). Fas induced rapid cell death in all three 
control transfectants (less than 10% viability at 48 hr), 
while the three bcl-xL transfectants remain greater than 
60% viable throughout the experiment. Neither the neo 
nor the bcl-xL transfectants demonstrated decreases in 
viability when no antibody or an isotype-matched control 
MAb (immunoglobulin M [IgM]) was used (data not shown). 
Thus, Bcl-xL could substantially block Fas-induced cell 
death in Jurkat cells. 
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Figure 7. Bcl-xL Protects Cells from Fas- and CDS-Mediated PCD and IL-2 Withdrawal-Induced PCD 
(A) Jurkat cells transfected with a /X/-X, expression vector (Bcl-xS or with vector alone (Neo) and cloned. Cells were treated with anti-Fas (left) or 
anti-CD3 (right) for the indicated time course and viability assessed by propidium iodide exclusion as described in the Experimental Procedures. 
The open symbols represent the Neo clones, while the closed symbols represent the B&XL clones. lsotype-matched control MAb had no effect 
on either of the transfectants viability (data not shown). Bcl-xL expression was confirmed in three clones from each transfection by Western blot 
analysis as described in the Experimental Procedures (bottom). The data are representative of eight experiments for anti-FaMnduced PCD and 
three experiments for anti-CD3 induced PCD. 
(B) The viability of parental CTLL-2 cells (open symbol) or two independent clones of CTLL-2 cells transfected with pSFFVNeo-bcl-xL (closed 
symbols) was assessed following IL-2 withdrawal (top). Viability was determined at the indicated timepoints by propidium iodide exclusion. B&XL 
expression in the parental cells and transfected clones was determined by Western blot analysis (bottom). The expression of B&xc seen in these 
clones is similar to that of antiCD3 plus antiCD28activated T cells when compared directly (data not shown). Similar data was observed in six 
independent experiments. 
Anti-CD3 cross-linking has also been reported to induce 
apoptosis in T cell clones and cell lines (Shi et al., 1989; 
Ucker et al., 1989). To examine the ability of Bcl-xL to 
prevent TCR-induced cell death, the Jurkat transfectants 
were stimulated with anti-CD3 and their survival followed. 
By 84 hr, anti-CD3 treatment had resulted in 30%~80% 
cell death in the cultures of Neo clones. In contrast, anti- 
CD9induced cell death was almost completely inhibited 
by the presence of Bcl-XL. (Figure 7A, left). 
Bcl-X~ Can Function Independently of IL-2 
to Enhance T Cell Survival 
Based on the analyses of the effect of IL-2 on the survival 
of T ceils activated through cross-linking of the TCR-CD3 
complex, it appears that IL-2 can function as a survival 
factor in maintaining the viability of antigen-activated T 
cells. Although it appears that CD28 costimulation results 
in T cell survival that is independent of the growth factor 
levels in the supernatant, it is difficult to rule out that 
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the enhanced survival of CDPB-stimulated cells was not 
merely the result of the high levels of IL-2 produced by 
CD28 costimulation. The high levels of IL-2 produced in 
CD28costimulated cells may make it impossible to elimi- 
nate completely the effects of lymphokines by serial wash- 
ing. The high levels of lymphokine produced by CD28- 
costimulated cells could potentially affect the cells in an 
autocrine fashion, even in the absence of detectable lym- 
phokine accumulation in cultured supernatants. 
To determine whether bc/-xL could protect T cells from 
PCD induced in response to IL-2 withdrawal, we examined 
whether b&x, could substitute for IL-2 in protecting an 
IL-2-dependent T cell line from undergoing PCD upon IL-2 
withdrawal. CTLL-2 is a T cell line whose survival and 
proliferation in culture is dependent on IL-2 (Gillis and 
Smith, 1977). These cells can not be induced to secrete 
their own IL-2 and are frequently used in bioassays for 
IL-2. CTLLP cells were transfected with abcl-XL-containing 
expression vector. Neomycin-resistant clones were as- 
sessed for Bcl-xL protein expression by Western blot analy- 
sis (Figure 78, bottom). The Bcl-xL expression levels in 
two of the clones were found to be similar to that of anti- 
CD3 plus anti-CD28-activated T cells (data not shown). 
These two Bcl-XL-expressing clones were tested for the 
ability to survive in culture in the absence of IL-2. Both 
bcl-xL-transfected clones had enhanced survival in the ab- 
sence of IL-2 when compared with the parental cell line 
(Figure 78, top). Thus, bcl-xL can function in the absence 
of IL-2 to enhance T cell survival. These clones were also 
tested for radiation-induced death in assays similar to 
these presented in Figure 2. Clones expressing Bcl-xL dis- 
played significant protection from radiation-induced death 
when compared with control cells tested either in the pres- 
ence or absence of IL-2 (data not shown). 
Expression of Bcl-xL via CD28 Costimulatlon 
Is Evolutionarily Conserved 
To determine whether the ability of CD28 costimulation 
to regulate Bcl-xL expression is conserved between mouse 
and human, cells isolated from murine lymph nodes were 
activated with soluble anti-CD3 and Bcl-xL expression as- 
sessed (Figure 8). As in human cells, resting murine lym- 
phocytes do not express any detectable Bcl-xL (Figure 8, 
lane 1). Solubleanti-CD3 treatment for24 hr induced Bcl-xL 
expression in T cells when accessory cells are present 
to deliver a costimulatory signal. This level of Bcl-xL was 
enhanced if this costimulatory signal was amplified by ad- 
dition of antiCD28. In contrast, the ability of soluble anti- 
CD3 to up-regulate Bcl-xL expression in the presence of 
accessory cells is almost completely inhibited by the addi- 
tion of CTLA-419, a reagent that prevents CD28 costimula- 
tion by competitively inhibiting the CD28 ligands 87-l and 
87-2 from interacting with CD28. These data demonstrate 
that in mouse T cells Bcl-xL expression is also induced 
during cell activation. Furthermore, at submitogenic doses 
of antiCD3, the induction of Bcl-XL expression is almost 
completely dependent on CD28 costimulation. This ex- 
pression pattern is consistent with Bcl-XL playing a role in 
activated T cell survival in the mouse. Consistent with this 
possibility, the viability of Thy-l-positive cells from the un- 
- 
separated lymph node cell population stimulated with anti- 
CD3 alone was 82% after 72 hr. In contrast, the addition 
of anti-CD28 enhances the viability of the Thy-l-positive 
cells to 88%. Conversely, by blocking CD28-B7-mediated 
costimulation within the lymph node cells with CTLA-419, 
viability of the activated T cells is reduced to 20% at 
72 hr. 
Discussion 
The data allow us to draw several conclusions regarding 
the susceptibility of human T cells to undergo PCD. By 
using y irradiation, a general inducer of PCD, as a probe, 
we have determined that the susceptibility of T cells to 
undergo PCD correlates with their state of activation. Rest- 
ing T cells appear to survive for prolonged periods of time 
in culture in the absence of additional environmental insult. 
However, resting 7: cells show little capacity to survive in 
the face of insults such as y irradiation. In contrast, T cells 
activated by cross-linking of the TCR-CD3 complex differ 
from resting T cells by demonstrating an enhanced ability 
to survive following treatment with y irradiation. However, 
this enhanced survival capability in response to environ- 
mental insult appears to be primarily dependent on the 
activity of external growth factors. In the absence of growth 
factors, antigen receptor-activated T cells will undergo 
cell death even in the absence of external insults, and 
their resistance to y irradiation is no greater than that of 
resting T cells. 
Costimulation through the CD28 receptor appears to 
play an important role in enhancing the resistance of anti- 
gen receptor-activated T cells to undergo PCD in culture. 
Murine LN 
anti-CD3 - + + + 
anti-CD28 - - + - 
CTLA4lg - - - + 
29 kDa- 
t-B&x, 
Figure 8. CD28 Costimulation Can Augment Bcl-xL Expression in Mu- 
rine Lymphocytes 
Lymph node cells from C57BU6 mice were treated with either anti-CD3 
alone or in combination with anti-CD28 or CTLA-4lg for 24 hr. Cells 
(5 x ICP) were harvested in NET-N and subjected to SDS-PAGE and 
Western blot analysis as described in Experimental Procedures. Anti- 
body addition is indicated by a (plus) or (minus) above each lane of 
the autoradiograph. The data are representative of three separate 
experiments. 
iF28 Costimulation Enhances Bcl-xL Expression 
Based on the above results, one obvious way in which 
CD28 costimulation enhances the survival of activated T 
cells is by augmenting the autocrine production of lympho- 
kines (Thompson et al., 1989). The ability of CD28 to en- 
hance lymphokine production will not only enhance the 
survival of the helper cell that produces lymphokines such 
a8 IL-2, but also provides extrinsic survival factors to neigh- 
boring antigen-activated T cells in a paracrine fashion. 
Thus, CD28 costimulation, by augmenting lymphokine 
production, is likely to affect the survival of not only the 
helper T cell, which receives costimulation through the 
CD28 receptor, but also additional antigen receptor-acti- 
vated cells incapable of producing the levels of lympho- 
kines needed for maintaining their own survival following 
antigen activation. 
Not only does CD28 costimulation enhance the produc- 
tion of extrinsic survival factors, CD28 costimulation also 
appears to increase the intrinsic ability of T cells to survive. 
CD28 costimulation was found to augment the expression 
of the cell survival gene bcl-xL. This augmentation of Bcl-xL 
expression by CD28 costimulation is likely to have an ef- 
fect on the ability of costimulated cells to suwive during 
an inflammatory response. CD28 costimulated cells ap- 
pear to be less dependent on extrinsic growth factors for 
their ability to suwive in culture. Taken together with the 
ability of IL-2dependent CTLLP cells transfected with bcl- 
xL to suwive for prolonged periods of time in culture in the 
absence of IL-2 or the ability of bc/-xL-transfected Jurkat 
cells to suwive Fas-induced PCD, Bcl-xL is likely to play 
a role in the ability of CD28 to enhance T cell survival. 
Our data also provides information concerning the po- 
tential roles of Bcl-2 and Bcl-xL in regulating T cell suwival. 
Our data demonstrate that Bcl-2 is constitutively ex- 
pressed in human T cells. This suggests that Bcl-2 func- 
tions to provide a basal cell survival capability. This is 
consistent with the observation that Bcl-2 is essential for 
the survival of resting T cells in culture (Nakayama et al., 
1993; Reed et al., 1992; Veis et al., 1993b). Resting T 
cells do not appear to express Bcl-xL protein, and therefore 
are likely to be absolutely dependent on Bcl-2 for establish- 
ing their intrinsic ability to suwive. 
The data also confirm previous reports that bcl-2 mRNA 
is induced upon T cell activation (Reed et al., 1987; Gran- 
inger et al., 1987). However, based on the simultaneous 
analysis of Bcl-2 protein levels, the data demonstrate that 
the induction of bcl-2 mRNA levels is apparently controlled 
only to allow the cell to maintain a steady-state level of 
Bcl-2 protein in relationship to total cellular protein. The 
induction of mRNA may allow T cell8 to increaSe Bcl-2 
protein levels in proportion to cell growth as the cells un- 
dergo blast transformation. 
In contrast with IX/-2 expression, b&x appears to un- 
dergo dynamic changes in expression in response to vari- 
ous forms of T cell activation. Resting T cells fail to express 
b&x. In T cells activated through the TCR, a low but signifi- 
cant level of bcl-xL mRNA is induced. Apparently, this level 
of M-x, expression is not suff icient to enhance the intrinsic 
survival of antigen-activated T cells significantly, since cells 
still seem to be dependent on external growth factors for 
their survival. A small amount of bcl-xs mRNA is also pro- 
duced upon TCR cross-linking, yet we were unable to detect 
accumulation of Bcl-xs protein within antigen-activated cells. 
Bcl-xL protein expression is up-regulated by CD28 costi- 
mulation. Up-regulation of Bcl-xL during T cell activation 
may play an important role in allowing cells to survive at 
sites of inflammation. 
The expression pattern of Bcl-xL in anti-CD3 plus anti- 
CDPB-activated T cells correlates well with the delay in 
the onset of Fas-induced cell death during T cell activation 
(Klas et al., 1993). Although Bcl-xL induction appears to 
be a sufficient explanation for the inability of Fas cross- 
linking to induce cell death during the first 48-72 hr after 
T cell activation, it may not be the only mechanism by 
which T cells acquire Fas-resistance. For instance, resting 
CD45RO cells express Fas on their surface and are not 
sensitive to Fas-induced cell death (Miyawaki et al., 1992). 
These cells are Bcl-x-negative (data not shown) and there- 
fore have acquired a Bcl-x-independent mechanism(s) of 
Fas resistance. 
In summary, our data demonstrate that bc/-2 and M-x 
play distinct and complementary roles in regulating T cell 
suwival. The coordinated regulation of these genes pro- 
vides a mechanism for the dynamic regulation of lympho- 
cyte survival during an immune response. 
Experimental Procedures 
Cell Culture 
Human T lymphocytes were isolated from the buffy coats of healthy 
donors by negative immunomagnetic selection as previously de- 
scribed (June et al., 1987). In brief, cells were subjected to a cocktail 
of antibodies to remove all cells except resting CDPEpositive T cells. 
T cells were cultured in RPM1 1840 supplemented with fetal calf serum 
(1 O%), L-glutamine (2 mM), penicillin-streptomycin (100 U/ml, 100 pgl 
ml),and HEPES(20mM).Cellswererestedovernightpriortoactivation 
or irradiation. T cells were activated with plate-immobilized anti-CD3 
(G19.4, 1 ug/ml) in the presence or absence of soluble antibody to 
CD28 (9.3) at 1 rg/ml. MAbs to CD2 (X2/18), CD5 (10.2), CD1 la 
(TS1/22), CD18 (TSl/i8), and MHC class I (W832) were also used at 
1 pg/ml. Stimulations were performed for the time periods indicated 
in the figures. For the irradiation experiments, cells were stimulated 
for 12 hr prior to removal from the culture dish and irradiated at 15 
Gy with a cesium source y irradiator (J. L. Shepherd, Incorporated). 
Prior to irradiation, cells were either left in the growth medium or 
washed three times and resuspended in fresh medium in the presence 
or absence of human recombinant IL-2 (200 U/ml, Soehringer- 
Mannheim). Following irradiation, cells were plated at 100,000 cells/ 
well in 98-well culture dishes (Costar) and viability and total cell num- 
bers were assessed by trypan blue exclusion (in duplicate) and propid- 
ium iodide exclusion (in duplicate, see below). 
For Fas-induced PCD studies, the anti-Fas MAb. CH-11 (Panvera) 
was used in soluble form at 0.5 &ml. Antibody was added at 24 hr 
intervals following anti-CD3 plus anti-CD28 activation of T cells and 
viability assessed by propidium iodide exclusion. Fas surface expres- 
sion was confirmed by staining with CH-11 for 30 min, followed by 
fluorescein isothiocyanate-conjugated anti-mouse IgM (Sigma) for 30 
min. Stained cells were analyzed by flow cytometry (FACSort, Secton- 
Dickinson) utilizing Lysis II software. 
Jurkat cells were maintained in medium as described above and 
transfected with pSFFVNeo-bcl-xL or pSFFVNeo by electroporation. 
Transfectants were selected with 6418 at 1 mg/ml and cloned by 
limiting dilution. Clones were stained for Fas expression as described 
above. Fas-induced PCD was performed at an antibody concentration 
of 10 @ml. Cells were washed and resuspended in fresh medium a1 
2.5 x lo5 cells/ml and treated with anti-Fas or an isotype-matched 
control. Viability was assessed by propidium iodide exclusion as de- 
scribed below. Anti-CDI-induced cell death was performed with plate- 
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bound anti-CD3 (OKT3) at 1 pg/ml and viability assessed daily by 
propidium iodide exclusion. 
CTLL-2 cells were maintained in the growth medium described 
above with addition of ff-mercaptoethanol (50 uM) and recombinant 
IL-2 (100 U/ml) (Nunez et al., 1990). Cells were transfected with the 
expression vector pSFFVN&/-XL (Boise etaf., 1993) byelectropora- 
tion with a Gene Pulser (BioRad) at 250 V and 960 pF. Transfectants 
were selected on 250 ug/ml 0418, with posttive clones determined 
by Western blot. For IL-2 deprivation studies, cells were plated in fresh 
medium at 3 x IO5 cells/ml 1 day prior to deprivation. Cells were then 
washed three times in fresh medium without IL-2 and resuspended 
in the same medium. Viability was assessed bypropidium iodideexclu- 
sion on indicated days. 
Lymph nodes were harvested from C57BUS mice (Jackson Labora- 
tories, Bar Harbor, Maine) and single cell suspensions were prepared 
by passage through nylon mesh. Cells were plated at 2 x l@/ml in 
complete medium consisting of DMEM (GIBCO BRL) supplemented 
with 10% fetal calf serum, penicillin (100 U/ml), streptomycin (100 
U/ml), 10 mM HEPES, 50 pM B-ME and 0.1 mM nonessential amino 
acids. Soluble anti-CD3 (145-2C11, 10 ug/ml, a gifl from J. Bluestone) 
was added alone or in combination with anti-CD28 (10 Kg/ml) or CTLA- 
4lg (100 ug/ml, a gift from G. Gray, Repligen). Cuhures were incubated 
for 24 hr at 37OC, 7% COI, and harvested for Western blot analysis. 
For viability studies cells were treated as described above. Viability 
of T cells following activation was assessed by propidium iodide exclu- 
sion of Thy-l-positive cells. 
RNA Isolation and Analyses 
RNA was isolated from T cells by centrifugation through guanidiuml 
CSCIZ gradients as previously described (June et al., 1987). Equal 
amounts of RNA (as assessed by ethidium bromide staining of 28 S 
ribosomal RNA electrophoresed on nondenaturing agarose gels) were 
loaded onto agarose/formaldehyde denaturing gels and separated by 
size. Gels were transferred to nitrocellulose (Schleicher and Schuell, 
Keene, New Hampshire) and baked under vacuum for 2 hr at 80°C. 
Blots were prehybridized at 42OC for 6 hr in Stark’s solution (50% 
formamide, 5x SSC [I x SSC is 0.15 M NaCI, 0.015 M sodium ci- 
trate], 1 x Denhardfs solution, 25 mM sodium phosphate [pH 6.51. 
250 gg Torula RNA per ml) and hybridized in Stark’s solution with 10% 
dextran sulfate and =P-labeled nick translated probes (1 x IO6 dpml 
ml) overnight at 42OC. The blots were probed and stripped sequentially 
with probes specific for human bcl-x~, murine bcl-2 (a gift from S. 
Korsmeyer), human leukocyte antigen, and human bsx. The human 
hex probe was generated by polymerase chain reaction with primers 
designed from the published sequence (Oltvai et al., 1993). 
RNase protection analysis was performed as per the specifications 
of a commercially available kit (Ambion). T cell RNA (3 ug) was hybrid- 
ized to a radiolabeled riboprobe that was generated by cutting the 
~&XL in pBluescript SK(+) plasmid with Accl and generating tran- 
scripts in vitro from the T3 promoter using a kit from Promega. The 
336 nt riboprobe was gel purified, extracted, and hybridized to T cell 
RNA for 16 hr at 42OC prior to the addition of a cocktail of RNaseA 
and RNaseTl. Protection of the probe by b~1-x~ mRNA should yield 
a fragment of 264 nt. while hybridization to the bcl-xs message should 
protect 163 nt of the radiolabeled probe. Protection products were 
separated on 5% acrylamide, 7 M urea sequencing gel. End-labeled 
pBluescript SKII digested with Hpall was used as a marker. Gels 
were dried down and exposed to XAR-5 film (Kodak). 
Productlon of Bcl-x Antibodies 
The open reading frame of bcl-xs was amplified by polymerase chain 
reaction with the primers (Y-GGA GAT ATA CAT ATG TCT CAG AGC 
AAC CGG GAG CTG GTG-3’ and 5’CGG GAT CCC GTC ATT TCC 
GAC TGA AGA GTG AGC CCA GCA G-3’) and cloned into the Ndel 
and BamHl sites of PET-3b (Novagen). Recombinant protein was pro- 
duced in BL21 cells by induction with 0.4 mM IPTG. This protein was 
determined to be in the insoluble fraction of a lysis of the bacteria and 
was partially purified in this manner. The insoluble fraction was washed 
with 2 M urea and solubilized with 6 M guanidine-HCL. The protein 
was renatured by a step dialysis through 3 M and 1 M guanidine- 
HCL, followed by dialysis against phosphate-buffered saline (pti 8.3) 
with 500 mM KCI. Protein concentration was determined by Bradford 
assay with a commercially available kit (BllRad) and protein purity 
was assessed by SDS-PAGE and Coomassie blue staining. 
For production of rabbit polyclonal antibodies, 1 mg of recombinant 
protein was suspended in complete Freunds adjuvant and injected 
subcutaneously into multiple sites on the back of the rabbit. Animals 
were boosted with 200 pg of protein in incomplete Freund’s adjuvant. 
Sera were screened by Western blot against recombinant protein and 
for specific immunoprecipitation using in vitro translated proteins and 
transfected cell lines. 
For production of MAbs, BALB/c mice were immunized with recom- 
binant Bcl-xs in polyacrylamide gel emulsified in complete Freund’s 
adjuvant injected subcutaneously in the hind footpads and intraperito- 
neally. Mice were boosted twice at 30 day intervals with a mixture 
of soluble and acrylamide-embedded gel-bound protein emulsified in 
incomplete Freund’s adjuvant. Spleen and lymph node cells were har- 
vested 3 days after the final boost and fused to P3X63-Ag8.653 my- 
eloma cells using standard techniques (Keamey, 1984). Hybridoma 
supernatants were tested 14 days after fusion for activity by enzyme- 
linked immunosorbent assay on wells coated with recombinant Bcl-xs 
at 5 @ml in borate-buffered saline (pH 8.4). Hybridoma supernatants 
that were positive by enzyme-linked immunosorbent assay were 
screened by Western blot against FL5.12 transfected with bcl-xL or 
b&Z’. Positive hybridoma lines were cloned by limiting dilution, re- 
screened, and then injected into pristane-primed BALB/c mice for asci- 
tes production. 
Immunopreclpftation and Western Blot Analyala 
T cells were activated as described above for indicated times. At each 
timepoint, 4 x 10’ cells from each of the culture conditions were iso 
lated and lysed in 1.0 ml NET-N (100 mM NaCI, 1 mM EDTA, 20 mM 
Tris [pH 8.0],0.2% NP-40). Nuclei and debris were spun out for 2 min 
in a microcentrifuge at 4*C. The supernatant was then precleared for 
30 min with 50 pl Pansorbin (Calbiochem). Following removal of the 
Pansorbin by centrifugation, the supernatant was split into two equal 
volumes (450 pl), to which either 1 pl of anti-B&x rabbit serum, or 
2.5 ug of the hamster anti&l-2 monoclonal 6C8 (Hockenbery et al., 
1990) was added. The lysates were rocked at 4OC for 1 hr prior to the 
addition of 25 pl of protein A-agarose (GIBCO BRL) for an additional 
30 min. The immunoprecipitates were pelleted and washed twice with 
NET-N and once with NET. 2 x SDS loading buffer (100 ul) was added 
to the pellet, which was snap frozen and kept at -20°C until the gel 
was run. 
lmmunoprecipitations were boiled and subjected to SDS-PAGE, 
through 15% gels. Gels were transferred to nitrocellulose by elec- 
troblotting using the BioRad transfer apparatus at 200 mA for 3 hr. 
Blots were blocked overnight at 4OC in 5% nonfat milk, 0.2% Tween 
20. Blots were hybridized with either the supernatant from the 2Al 
monoclonal against Bcl-x (1:lO) or purified 6C8 MAb (1:200) in the 
blocking solution described above. Westerns were developed using 
the enhanced chemiluminescence system (Amersham) with Hyperfilm 
(Amersham). 
Jurkat and T cells were lysed in NET-N and protein was quantitated 
by bicinchoninic acid (Pierce). Protein (100 pg) was run in each lane 
of a 15% SDS-PAGE and Western blots were performed as described 
above. 
CTLL-2 cells (2.5 x IO”) and murine lymphocytes (5 x 107 were 
lysed in 50 pl of NET-N and the nuclei and debris removed as above. 
2 x SDS loading buffer (50 ul) was added to the supernatant and SDS- 
PAGE and Western blotting was performed as described above. 
Propldlum Iodide Exclusion Assays 
At indicated timepoints, two separate samples of 2 x 105 cells were 
pelleted and resuspended in 0.5 ml of phosphate-buffered saline sup- 
plemented with 1% bovine serum albumin and 0.01% sodium azide. 
We added 2 ul of propidium iodide (0.5 mglml) to the cells and samples 
were then analyzed by FACS using a FACSort and Lysis II software. 
Percent viability was determined by dividing the number of cells that 
excluded propidium iodide (viable) by the total number of cells. For- 
ward light scatter characteristics of living cells were utilized to delete 
debris from the analyses. 
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